Quick Answer
GALECTIN THERAPEUTICS INC reported Diluted EPS of $0.48 per share (loss) for fiscal year 2025.
GALECTIN THERAPEUTICS INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.48 | +36.8% |
| 2024 | -$0.76 | -2.7% |
| 2023 | -$0.74 | -13.8% |
| 2022 | -$0.65 | -25.0% |
| 2021 | -$0.52 | -26.8% |
| 2020 | -$0.41 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.13 | +27.8% | -8.3% |
| June 30, 2025 | -$0.12 | +40.0% | +20.0% |
| March 31, 2025 | -$0.15 | +21.1% | +16.7% |
| September 30, 2024 | -$0.18 | +25.0% | +10.0% |
| June 30, 2024 | -$0.20 | -33.3% | -5.3% |
| March 31, 2024 | -$0.19 | +0.0% | +20.8% |
| September 30, 2023 | -$0.24 | -71.4% | -60.0% |
| June 30, 2023 | -$0.15 | +6.3% | +21.1% |
- GALECTIN THERAPEUTICS INC showed an increase of +36.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, GALECTIN THERAPEUTICS INC’s diluted eps has declined by 17.1% (from $0.41 per share (loss) to $0.48 per share (loss)).
- The most recent figure is from GALECTIN THERAPEUTICS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: